Navigation Links
ViroPharma Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema
Date:12/12/2012

reatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unregulated, can initiate or perpetuate an attack by consuming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. Patients with HAE experience approximately 20 to 100 days of incapacitation per year. There are estimated to be at least 6,500 people with HAE in the United States and at least 10,000 people in the European Union.

For more information on HAE, visit the U.S. HAE Association's website at www.haea.org and the HAEi's (International Patient Organization for C1 Inhibitor Deficiencies) website at www.haei.org.

About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options.  ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, Friedreich's Ataxia, and adrenal insufficiency, cytomegalovirus (CMV); and recurrent C. difficile infection (CDI).  Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve.  ViroPharma's com
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
2. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
3. ViroPharma To Participate In The JMP Securities Healthcare Conference
4. Berger & Montague, P.C. Reminds Viropharma Shareholders That The Deadline To Petition The Court To Act As Lead Plaintiff Is July 23, 2012
5. ViroPharma To Release 2012 Second Quarter Financial Results On August 9, 2012
6. ViroPharma Incorporated Reports Second Quarter 2012 Financial Results
7. ViroPharma to Present at the Stifel Nicolaus 2012 Healthcare Conference
8. ViroPharma To Host Analyst And Investor Seminar On September 21, 2012
9. ViroPharma Incorporated Reports Third Quarter 2012 Financial Results
10. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
11. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... from its pivotal field study of AT-001 (Grapiprant), ... dogs with osteoarthritis.  In the study, dogs receiving ... were statistically significant compared to placebo (p<0.05) at ...
(Date:12/17/2014)... STUTTGART, Germany , December 17, 2014 ... high level of expenditure on research and development ... ZEISS increased its revenue by two percent to EUR 4.287 ... Earnings (EBIT) grew by 14 percent to EUR 360 million. ... Group," said Dr. Michael Kaschke , President and CEO ...
(Date:12/17/2014)... 17, 2014 , ... a hub of information concerning the biopharmaceutical Group,s national and ... further addition to the recently launched institutional website that is ... been enriched by a new chapter in the fascinating story ... richly detailed and panoramic hub on the world of clinical ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3
... , ATLANTA, Nov. 6 GeoVax Labs, Inc. ... an Atlanta-based, biopharmaceutical company developing human vaccines for diseases ... agents, today announced its third quarter 2009 financial results ... President and Chief Executive Officer commented, "We are pleased ...
... PARIS, November 6 , ... Oral Agent Linezolid for the,Treatment of Multi-Resistant Staphylococcus Aureus ... speciality pharmaceutical company focused on the discovery and,development of ... microbial resistance, announces today that its most advanced oral,antibacterial ...
Cached Medicine Technology:GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 2GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 3GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 4GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 5GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 6GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 7GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 8Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4
(Date:12/19/2014)... 19, 2014 The Plantrician ... developing educational events, tools and resources for healthcare ... School , the world’s leading online cooking school, ... human being needs: Culinary Rx. As an online ... Culinary Rx, scheduled for debut spring 2015, will ...
(Date:12/19/2014)... An evening dress is perfect for any occasion and is ... dresses retailer, has unveiled its new selection of evening dresses. ... shopping platform. Customers can view more at its ... been accepted and praised by customers for many years. It ... clients. In order to expand its market share, the company ...
(Date:12/19/2014)... All children should have their eyesight checked between the ... experts say. The new vision-screening guidelines for preschool-aged ... National Center for Children,s Vision Health. The panel ... for eye problems, particularly vision issues that require ... strabismus (a disorder of eye alignment). Early detection ...
(Date:12/19/2014)... Older adults who have lost all their teeth have faster ... have at least some of their teeth, a new study ... provide an early warning of increased risk of physical and ... However, the findings don,t prove that tooth loss causes the ... 3,100 participants 60 and older. People with no remaining teeth ...
(Date:12/19/2014)... B. E. Smith, the only full-service leadership ... retained to lead a national chief financial officer ... The top executive search firm in the healthcare industry, ... healthcare executives into organizations. , Johnson Memorial Hospital ... to the residents of Johnson County and the surrounding ...
Breaking Medicine News(10 mins):Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2Health News:Preschoolers Need Eye Screening, Experts Say 2Health News:Loss of Teeth Linked to Physical, Mental Decline in Study 2Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 3
... federal program designed to help metropolitan public health ... after a large-scale,bioterror attack or natural disease outbreak ... to a new RAND Corporation study. , Researchers ... active in 72 metropolitan areas, appears to have ...
... TARPON SPRINGS, Fla., March 24 A report released ... a formal acknowledgement from the U.S. Food and Drug ... to illegally mislabel shrimp products to avoid paying antidumping ... Southern Shrimp Alliance (SSA), which repeatedly has voiced concern ...
... changes. , ... Milwaukee, WI (Vocus) ... provider of Individual Medical, Small Group and Specialty health insurance ... they face economic hardship., , , , ,“In these challenging ...
... to reduce risks of getting blood sugar disease, survey ... than half of Americans fear developing diabetes, but many ... getting the blood sugar disease, a new survey shows. ... they think, ,It,s not going to happen to me," ...
... Arabia, Kuwait, the United Arab Emirates and other countries ... 1 and 2 for the First International Cardiovascular Conference: ... event, this conference will bring together experts from across ... physicians from Western and Middle Eastern societies. , The ...
... , ... St. Cloud, Minn. (Vocus) March 24, 2009 ... to St. Cloud Area School District 742 public elementary schools on ... low-income and uninsured children. Smiles Across Minnesota provides children ages three ...
Cached Medicine News:Health News:Study finds program has improved health agencies' preparedness for bioterror and disease outbreaks 2Health News:GAO Study Links Duty Circumvention with Evasion of Food Safety Laws 2Health News:GAO Study Links Duty Circumvention with Evasion of Food Safety Laws 3Health News:Assurant Health Helps People Keep Their Insurance 2Health News:Assurant Health Helps People Keep Their Insurance 3Health News:Many Americans Fear Being Diagnosed With Diabetes 2Health News:Many Americans Fear Being Diagnosed With Diabetes 3Health News:Smiles Across Minnesota Expands Program to St. Cloud 2Health News:Smiles Across Minnesota Expands Program to St. Cloud 3Health News:Smiles Across Minnesota Expands Program to St. Cloud 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: